FDA has issued a final questions and answers guidance on on GDUFA implementation related to: • self-identification of facilities, sites, and organizations • review of generic drug submissions, and • inspections and compliance. The Q&A includes 39 questions and answers to help clarify some of the issues included in previous versions. Questions and answers related to GDUFA user fee provisions were published in November, 2016.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
